Compound Semaglutide
US$ 20.38
glp-1 receptor agonist blood pressure reduction Cardiovascular Effects of Glucagon-Like Peptide-1 Agonists Mechanisms of action and effects
Description
Diabetes Obes Metab (2018) 20(2):46873
doi: 10.1210/mend.13.9.0340
Recent advances in TfR-targeting platforms have substantially improved CNS distribution, enabling the approval of two BBB-penetrant enzyme replacement therapies for Hunter syndrome
A similar concept has emerged in metabolic disease drug discovery research, although it is fundamentally different from the oncology field, because the effector molecule is not meant to drive a cell-killing effect but a cell-altering effect
Do D, Lee T, Peasah SK, Good CB, Inneh A, Patel U
